{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:31:52Z","timestamp":1790767912692,"version":"4.1.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016925","name":"Takeda Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Approximately one out of every 88 seniors has inflammatory bowel disease (IBD), and this is expected to increase in the future. They are more likely to have left-sided disease in ulcerative colitis, and isolated colonic disease in Crohn\u2019s disease; perianal disease is less common. Other common diagnoses in the elderly must also be considered when they initially present to a healthcare provider. Treatment of the elderly is similar to younger persons with IBD, though considerations of the increased risk of infections and malignancy must be considered when using immune modulating drugs. Whether anti-TNF therapies increase the risk of infections is not definitive, though newer biologics, including vedolizumab and ustekinumab, are thought to be safer with lower risk of adverse events. Polypharmacy and frailty are other considerations in the elderly when choosing a treatment, as frailty is associated with worse outcomes. Costs for IBD-related hospitalizations are higher in the elderly compared with younger persons. When elderly persons with IBD are cared for by a gastroenterologist, their outcomes tend to be better. However, as elderly persons with IBD continue to age, they may not have access to the same care as younger people with IBD due to deficiencies in their ability to use or access technology.<\/jats:p>","DOI":"10.1093\/jcag\/gwad013","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T15:18:37Z","timestamp":1693927117000},"page":"S45-S54","source":"Crossref","is-referenced-by-count":16,"title":["The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations\u2014IBD in Seniors"],"prefix":"10.1093","volume":"6","author":[{"given":"Seth R","family":"Shaffer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg, Manitoba , Canada"},{"name":"University of Manitoba IBD Clinical and Research Centre , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-8426","authenticated-orcid":false,"given":"M Ellen","family":"Kuenzig","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7539-9103","authenticated-orcid":false,"given":"Joseph W","family":"Windsor","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre IBD Centre, McGill University , Montr\u00e9al, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Jones","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Clinical Health, and Epidemiology, Dalhousie University , Halifax, Nova Scotia , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Lee","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K","family":"Murthy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa , Ottawa, Ontario , Canada"},{"name":"The Ottawa Hospital IBD Centre , Ottawa, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura E","family":"Targownik","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-525X","authenticated-orcid":false,"given":"Juan-Nicol\u00e1s","family":"Pe\u00f1a-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Community Health and Epidemiology, University of Saskatchewan , Saskatoon , Saskatchewan , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-027X","authenticated-orcid":false,"given":"Noelle","family":"Rohatinsky","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Saskatchewan , Saskatoon , Saskatchewan , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ghandeharian","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0021-2161","authenticated-orcid":false,"given":"Parul","family":"Tandon","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Health Network, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"St-Pierre","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Natt","sequence":"additional","affiliation":[{"name":"Northern Ontario School of Medicine University , Sudbury, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Davis","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Weinstein","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H B","family":"Im","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-3598","authenticated-orcid":false,"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"ICES , Toronto, Ontario , Canada"},{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario , Canada"},{"name":"Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0556","authenticated-orcid":false,"given":"Gilaad G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Goddard","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gorospe","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Bergevin","sequence":"additional","affiliation":[{"name":"\u00c9cole de kin\u00e9siologie et des sciences de l\u2019activit\u00e9 physique, Facult\u00e9 de m\u00e9decine , Universit\u00e9\u0301 de Montr\u00e9al, Montreal, Quebec , Canada"},{"name":"Centre de recherche de l\u2019Institut universitaire de g\u00e9riatrie de Montr\u00e9al , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Silver","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawna","family":"Bowles","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Stewart","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Pearlstein","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H","family":"Dawson","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8041-3574","authenticated-orcid":false,"given":"Charles N","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg, Manitoba , Canada"},{"name":"University of Manitoba IBD Clinical and Research Centre , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"issue":"1","key":"2023090515140509200_CIT0001","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.gastro.2020.08.060","article-title":"AGA clinical practice update on management of inflammatory bowel disease in elderly patients: Expert review","volume":"160","author":"Ananthakrishnan","year":"2021","journal-title":"Gastroenterology"},{"issue":"7, Supplement","key":"2023090515140509200_CIT0002","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/S0016-5085(22)60984-3","article-title":"Sa1557: forecasting the incidence and prevalence of IBD: A Canadian nation-wide analysis","volume":"162","author":"Coward","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"2023090515140509200_CIT0003","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jgh.13826","article-title":"Clinical characteristics and long-term prognosis of elderly onset ulcerative colitis","volume":"33","author":"Song","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"2023090515140509200_CIT0004","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/flgastro-2019-101218","article-title":"How to manage IBD in the \u2018elderly\u2019","volume":"11","author":"Segal","year":"2020","journal-title":"Frontline Gastroenterol"},{"issue":"3","key":"2023090515140509200_CIT0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/gutjnl-2018-317572","article-title":"Mortality in adult-onset and elderly-onset IBD: A nationwide register-based cohort study 1964-2014","volume":"69","author":"Olen","year":"2020","journal-title":"Gut"},{"issue":"11","key":"2023090515140509200_CIT0006","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.cgh.2020.02.048","article-title":"Progression of elderly onset inflammatory bowel diseases: A systematic review and meta-analysis of population-based cohort studies","volume":"18","author":"Rozich","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2023090515140509200_CIT0007","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/ecco-jcc\/jjaa181","article-title":"Epidemiology and natural history of elderly-onset inflammatory bowel disease: Results from a territory-wide Hong Kong IBD Registry","volume":"15","author":"Mak","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2023090515140509200_CIT0008","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000507115","article-title":"Follow-up ileocolonoscopy is underused in Crohn\u2019s disease patients after ileocecal resection despite higher total and inpatient health-care costs compared to controls","volume":"5","author":"Vavricka","year":"2020","journal-title":"Inflamm Intest Dis"},{"issue":"2","key":"2023090515140509200_CIT0009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000522569","article-title":"Elderly patients with moderate-to-severe ulcerative colitis are more likely to have treatment failure and adverse outcome","volume":"69","author":"Zhang","year":"2022","journal-title":"Gerontology"},{"issue":"8","key":"2023090515140509200_CIT0010","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/ibd\/izaa308","article-title":"Disease- and treatment-related complications in older patients with inflammatory bowel diseases: Comparison of adult-onset vs elderly-onset disease","volume":"27","author":"Rozich","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"2023090515140509200_CIT0011","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","article-title":"Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: A nationwide cohort study","volume":"16","author":"Khan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2023090515140509200_CIT0012","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/ibd\/izx089","article-title":"Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases","volume":"24","author":"Nguyen","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"2023090515140509200_CIT0013","first-page":"462","article-title":"Risk of infection and types of infection among elderly patients with inflammatory bowel disease: A retrospective database analysis","volume":"26","author":"Khan","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2023090515140509200_CIT0014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ibd.20628","article-title":"Inflammatory bowel disease in the elderly is associated with worse outcomes: A national study of hospitalizations","volume":"15","author":"Ananthakrishnan","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"2023090515140509200_CIT0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jgh.15454","article-title":"Advanced therapies in inflammatory bowel disease: Special considerations","volume":"36","author":"Williams","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"2023090515140509200_CIT0016","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/ecco-jcc\/jjw054","article-title":"Systematic review and meta-analysis: Phenotype and clinical outcomes of older-onset inflammatory bowel disease","volume":"10","author":"Ananthakrishnan","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2023090515140509200_CIT0017","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2012-303864","article-title":"Natural history of elderly-onset inflammatory bowel disease: A population-based cohort study","volume":"63","author":"Charpentier","year":"2014","journal-title":"Gut"},{"issue":"5","key":"2023090515140509200_CIT0018","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/apt.14494","article-title":"Phenotype and natural history of elderly onset inflammatory bowel disease: A multicentre, case\u2013control study","volume":"47","author":"Ma\u00f1osa","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2023090515140509200_CIT0019","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40266-020-00744-3","article-title":"Persistence on anti-tumour necrosis factor therapy in older patients with inflammatory bowel disease compared with younger patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)","volume":"37","author":"Porcari","year":"2020","journal-title":"Drugs Aging"},{"issue":"7","key":"2023090515140509200_CIT0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/ecco-jcc\/jjaa012","article-title":"Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients","volume":"14","author":"de Jong","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2023090515140509200_CIT0021","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cgh.2020.04.070","article-title":"Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: Patient-level pooled analysis of data from randomized trials","volume":"19","author":"Cheng","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"2023090515140509200_CIT0022","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1111\/bcp.14785","article-title":"The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases","volume":"87","author":"Kantasiripitak","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"2023090515140509200_CIT0023","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/apt.15214","article-title":"Early combined immunosuppression may be effective and safe in older patients with Crohn\u2019s disease: Post hoc analysis of REACT","volume":"49","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2023090515140509200_CIT0024","first-page":"170","article-title":"Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: An observational multicenter UK experience","volume":"33","author":"Ibraheim","year":"2020","journal-title":"Ann Gastroenterol"},{"issue":"5","key":"2023090515140509200_CIT0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/ibd\/izab163","article-title":"Efficacy of Vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients","volume":"28","author":"Khan","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"2023090515140509200_CIT0026","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/2050640620951400","article-title":"Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: A binational, multicenter, retrospective cohort study","volume":"8","author":"Cohen","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"7","key":"2023090515140509200_CIT0027","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s10620-021-07129-5","article-title":"Safety and efficacy of vedolizumab versus tumor necrosis factor \u03b1 antagonists in an elderly IBD population: A single institution retrospective experience","volume":"67","author":"Pabla","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"7","key":"2023090515140509200_CIT0028","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.15177","article-title":"Comparative safety and effectiveness of tumor necrosis factor \u03b1 antagonists and vedolizumab in elderly IBD patients: A multicentre study","volume":"49","author":"Adar","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2023090515140509200_CIT0029","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1007\/s10620-021-07117-9","article-title":"Real-world effectiveness and safety of ustekinumab in elderly Crohn\u2019s disease patients","volume":"67","author":"Garg","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"9","key":"2023090515140509200_CIT0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/2050640620948802","article-title":"Effectiveness and safety of vedolizumab in biologically na\u00efve patients: A real-world multi-centre study","volume":"8","author":"Macaluso","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2023090515140509200_CIT0031","first-page":"237","article-title":"An Australian real-world study of treatment persistence of ustekinumab in Crohn\u2019s disease","volume":"15","author":"Chien","year":"2021","journal-title":"Biologics"},{"issue":"5","key":"2023090515140509200_CIT0032","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"issue":"9701","key":"2023090515140509200_CIT0033","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"2023090515140509200_CIT0034","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2050640619889763","article-title":"Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines","volume":"8","author":"Wisniewski","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"7","key":"2023090515140509200_CIT0035","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/apt.15458","article-title":"Increased risk of thiopurine-related adverse events in elderly patients with IBD","volume":"50","author":"Calafat","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2023090515140509200_CIT0036","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1053\/j.gastro.2020.05.065","article-title":"Impact of anti-tumor necrosis factor and thiopurine medications on the development of COVID-19 in patients with inflammatory bowel disease: A nationwide veterans administration cohort study","volume":"159","author":"Khan","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"2023090515140509200_CIT0037","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00384-020-03716-6","article-title":"Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events","volume":"35","author":"Asscher","year":"2020","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"2023090515140509200_CIT0038","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.16610","article-title":"The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: A nationwide cohort study of 56 410 IBD patients","volume":"55","author":"Khan","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2023090515140509200_CIT0039","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.15692","article-title":"Systematic review with meta-analysis: Biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease","volume":"51","author":"Piovani","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2023090515140509200_CIT0040","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: A systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2023090515140509200_CIT0041","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and Crohn\u2019s disease: 4 years of global post-marketing data","volume":"14","author":"Cohen","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"8","key":"2023090515140509200_CIT0042","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2023090515140509200_CIT0043","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1007\/s12325-021-01713-x","article-title":"Incidence of infections and malignancy among elderly male patients with IBD exposed to vedolizumab, prednisone, and 5-ASA medications: A nationwide retrospective cohort study","volume":"38","author":"Khan","year":"2021","journal-title":"Adv Ther"},{"issue":"6","key":"2023090515140509200_CIT0044","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cgh.2021.08.047","article-title":"Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2023090515140509200_CIT0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/apt.15538","article-title":"Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data","volume":"51","author":"Card","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2023090515140509200_CIT0046","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2023090515140509200_CIT0047","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"2023090515140509200_CIT0048","doi-asserted-by":"crossref","first-page":"e005892","DOI":"10.1161\/JAHA.117.005892","article-title":"Inflammatory bowel disease and risk of ischemic heart disease: An updated meta-analysis of cohort studies","volume":"6","author":"Feng","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2023090515140509200_CIT0049","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jocd.2019.07.009","article-title":"Bone health in patients with inflammatory bowel diseases","volume":"23","author":"Chedid","year":"2020","journal-title":"J Clin Densitom"},{"issue":"5","key":"2023090515140509200_CIT0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/apt.16444","article-title":"Comorbidity before and after a diagnosis of inflammatory bowel disease","volume":"54","author":"Bernstein","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2023090515140509200_CIT0051","doi-asserted-by":"crossref","first-page":"788980","DOI":"10.3389\/fonc.2021.788980","article-title":"The incidence rate and risk factors of malignancy in elderly-onset inflammatory bowel disease: A Chinese cohort study from 1998 to 2020","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"2023090515140509200_CIT0052","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1007\/s10620-012-2083-x","article-title":"Geriatric inflammatory bowel disease: Phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity","volume":"57","author":"Juneja","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"10","key":"2023090515140509200_CIT0053","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.cgh.2020.08.010","article-title":"Frailty is independently associated with mortality and readmission in hospitalized patients with inflammatory bowel diseases","volume":"19","author":"Qian","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2023090515140509200_CIT0054","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1007\/s10620-020-06746-w","article-title":"Increasing prevalence of frailty and its association with readmission and mortality among hospitalized patients with IBD","volume":"66","author":"Faye","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"8","key":"2023090515140509200_CIT0055","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1053\/j.gastro.2020.02.032","article-title":"Pretreatment frailty is independently associated with increased risk of infections after immunosuppression in patients with inflammatory bowel diseases","volume":"158","author":"Kochar","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515140509200_CIT0056","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1016\/j.cgh.2021.06.015","article-title":"Deficits in geriatric assessment associate with disease activity and burden in older patients with inflammatory bowel disease","volume":"20","author":"Asscher","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023090515140509200_CIT0057","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2147\/CLEP.S178056","article-title":"Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: A population-based study","volume":"10","author":"Benchimol","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"9","key":"2023090515140509200_CIT0058","doi-asserted-by":"crossref","first-page":"e2015899","DOI":"10.1001\/jamanetworkopen.2020.15899","article-title":"Association of continuity of care with outcomes in US veterans with inflammatory bowel disease","volume":"3","author":"Cohen-Mekelburg","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2023090515140509200_CIT0059","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jgh3.12631","article-title":"Assessing effectiveness and patient perceptions of a novel electronic medical record for the management of inflammatory bowel disease","volume":"5","author":"Kaazan","year":"2021","journal-title":"JGH Open"},{"issue":"2","key":"2023090515140509200_CIT0060","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1093\/jcag\/gwz048","article-title":"Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: A population-based cohort study","volume":"4","author":"Kuenzig","year":"2021","journal-title":"J Can Assoc Gastroenterol"},{"issue":"1","key":"2023090515140509200_CIT0061","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & colitis foundation","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2023090515140509200_CIT0062","doi-asserted-by":"crossref","first-page":"128","DOI":"10.14309\/ajg.0000000000000503","article-title":"Longitudinal trends in the direct costs and health care utilization ascribable to inflammatory bowel disease in the biologic era: Results from a Canadian population-based analysis","volume":"115","author":"Targownik","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2023090515140509200_CIT0063","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"2023090515140509200_CIT0064","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1093\/jcag\/gwab016","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for immunizations in patients with inflammatory bowel disease (IBD)-part 2: Inactivated vaccines","volume":"4","author":"Jones","year":"2021","journal-title":"J Can Assoc Gastroenterol"},{"issue":"6","key":"2023090515140509200_CIT0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/ibd\/izz189","article-title":"The association of medications and vaccination with risk of pneumonia in inflammatory bowel disease","volume":"26","author":"Gregory","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"30","key":"2023090515140509200_CIT0066","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1016\/j.vaccine.2021.05.043","article-title":"Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease","volume":"39","author":"Kochhar","year":"2021","journal-title":"Vaccine"},{"issue":"9","key":"2023090515140509200_CIT0067","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.dld.2021.04.015","article-title":"Vaccinations and inflammatory bowel disease\u2014a systematic review","volume":"53","author":"Chan","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"3","key":"2023090515140509200_CIT0068","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease","volume":"185","author":"Al-Janabi","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10","key":"2023090515140509200_CIT0069","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"issue":"3","key":"2023090515140509200_CIT0070","doi-asserted-by":"crossref","first-page":"462","DOI":"10.14309\/ajg.0000000000001619","article-title":"Factors affecting initial humoral immune response to SARS-CoV-2 vaccines among patients with inflammatory bowel diseases","volume":"117","author":"Kappelman","year":"2022","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/6\/Supplement_2\/S45\/51359272\/gwad013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/6\/Supplement_2\/S45\/51359272\/gwad013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T15:19:04Z","timestamp":1693927144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/6\/Supplement_2\/S45\/7260518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":70,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2023,9,5]]},"published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwad013","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,9,1]]}}}